Matinas: Positive Interim Data from Phase 2 Trial of MAT2203 for Cryptococcal Meningitis

 Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203  

Mean Early Fungicidal Activity (EFA) of the rate of yeast clearance in cerebrospinal fluid exceeded the prespecified primary endpoint threshold of >0.20 CFU/mL, CSF/day

Favorable safety and tolerability data support longer-term use of MAT2203 with no evidence of kidney toxicity seen with 6 weeks of oral MAT2203 treatment

Overall survival data from Cohorts 2 and 4 of EnACT trial (Cohorts 1 and 3 were safety lead-ins) provide clinically meaningful evidence of the safety and efficacy of MAT2203 for both a step-down indication and an all-oral treatment regimen for cryptococcal meningitis

Phase 3 registration trial of MAT2203 for treatment of cryptococcal meningitis to commence Q1 2023

https://www.biospace.com/article/releases/matinas-biopharma-announces-positive-interim-data-from-the-phase-2-enact-trial-of-mat2203-for-the-treatment-of-cryptococcal-meningitis-exceeding-primary-endpoint-threshold-patient-survival-in-all-oral-cohort-4-regimen-currently-90-percent-/